公开(公告)号：US09644038B2

公开(公告)日：2017-05-09

申请号：US13719785

申请日：2012-12-19

申请人： The Regents of the University of California ,  Lawrence Livermore National Security, LLC

发明人： Juntao Luo ,  Wei He ,  Kit S. Lam ,  Paul Henderson ,  Matthew Coleman ,  R. Holland Cheng ,  Li Xing

IPC分类号： C07K14/00 ,  C07K17/02 ,  C07K14/775

CPC分类号： C07K17/02 ,  C07K14/775

摘要： The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

公开(公告)号：US20170107261A1

公开(公告)日：2017-04-20

申请号：US15312582

申请日：2015-05-18

申请人： The Regents of the University of California

发明人： R. Holland Cheng ,  Li Xing ,  Chun Chieh Chen ,  Marie Stark

IPC分类号： C07K14/005 ,  A61K9/51

CPC分类号： C07K14/005 ,  A61K9/5169 ,  A61K2039/5258 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28142 ,  C12N2810/40 ,  G01N2333/08

摘要： Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

公开(公告)号：US20150118319A1

公开(公告)日：2015-04-30

申请号：US14533531

申请日：2014-11-05

申请人： The Regents of the University of California

发明人： R. Holland Cheng ,  Li Xing

IPC分类号： C07K14/005 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K9/5184 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  C07K16/10 ,  C07K16/1063 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/28142

摘要： This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.

摘要翻译： 本发明提供了用于免疫保护系统的口腔/粘膜，双重模态激活的肽/核酸组合物。

公开(公告)号：US10053494B2

公开(公告)日：2018-08-21

申请号：US15312582

申请日：2015-05-18

申请人： The Regents of the University of California

发明人： R. Holland Cheng ,  Li Xing ,  Chun Chieh Chen ,  Marie Stark

IPC分类号： C07K14/00 ,  C07K14/005 ,  A61K9/51

CPC分类号： C07K14/005 ,  A61K9/5169 ,  A61K2039/5258 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28142 ,  C12N2810/40 ,  G01N2333/08

摘要： Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

公开(公告)号：US09637524B2

公开(公告)日：2017-05-02

申请号：US14533531

申请日：2014-11-05

申请人： The Regents of the University of California

发明人： R. Holland Cheng ,  Li Xing

IPC分类号： A61K38/00 ,  C07K14/005 ,  A61K39/21 ,  A61K39/29 ,  C07K16/10 ,  C12N7/00 ,  A61K9/51 ,  A61K39/12 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K9/5184 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/542 ,  C07K16/10 ,  C07K16/1063 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/28142

摘要： This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.